Neurological Sciences

, Volume 23, Issue 1, pp 41–43

Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease

Authors

  • G. Fabbrini
    • Department of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • P. Barbanti
    • Department of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • C. Aurilia
    • Department of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • C. Pauletti
    • Department of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • G. L. Lenzi
    • Department of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
  • G. Meco
    • Department of Neurological Sciences, La Sapienza University, Viale del’Università 30, I-00185 Rome, Italy
ORIGINAL

DOI: 10.1007/s100720200022

Cite this article as:
Fabbrini, G., Barbanti, P., Aurilia, C. et al. Neurol Sci (2002) 23: 41. doi:10.1007/s100720200022
  • 333 Views

Abstract

As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson’s disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.

Key words Parkinson’s diseaseHallucinationsDelusionsDonezepil

Copyright information

© Springer-Verlag Italia 2002